Literature DB >> 1974497

Pharmacological characteristics of the stereoisomers of carvedilol.

W Bartsch1, G Sponer, K Strein, B Müller-Beckmann, L Kling, E Böhm, U Martin, H O Borbe.   

Abstract

The racemic compound carvedilol possesses two complementary pharmacological effects, vasodilation and beta-blockade. The R- and S-enantiomers of carvedilol and the racemate were investigated with respect to the beta-blocking, vasodilating, and hypotensive actions. In agreement with results obtained with other beta-blockers, only the S-enantiomer of carvedilol exerts beta-blocking effects. In contrast, no substantial difference between the enantiomers could be seen with respect to alpha-blockade. The greater hypotensive activity of S-carvedilol may be attributed to beta-blockade, which inhibits counter-regulatory mechanisms provoked by vasodilation. From these results it is concluded that there is a rationale for using carvedilol as the racemate. Using the S-enantiomer would lead to relatively strong beta-blockade with only a weak vasodilating effect. The R-enantiomer alone would act only as a hypotensive agent without beta-blockade.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1974497     DOI: 10.1007/bf01409475

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  A pithed rat preparation suitable for assaying pressor substances.

Authors:  R E SHIPLEY; J H TILDEN
Journal:  Proc Soc Exp Biol Med       Date:  1947-04

2.  Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology.

Authors:  E J Ariëns
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

3.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

4.  The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias.

Authors:  A M Barrett; V A Cullum
Journal:  Br J Pharmacol       Date:  1968-09       Impact factor: 8.739

5.  Haemodynamic effects of carvedilol, a new beta-adrenoceptor blocker and precapillary vasodilator in essential hypertension.

Authors:  R Eggertsen; R Sivertsson; L Andrén; L Hansson
Journal:  J Hypertens       Date:  1984-10       Impact factor: 4.844

6.  Studies on the mode of vasodilating action of carvedilol.

Authors:  G Sponer; K Strein; B Müller-Beckmann; W Bartsch
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

7.  Pharmacological profile of carvedilol, a compound with beta-blocking and vasodilating properties.

Authors:  K Strein; G Sponer; B Müller-Beckmann; W Bartsch
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

8.  Acute hemodynamic effects of the vasodilating and beta-blocking agent carvedilol in comparison to propranolol.

Authors:  T Wendt; R van der Does; R Schräder; H Landgraf; G Kober
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

9.  Effects of carvedilol on common carotid arterial flow, peripheral hemodynamics, and hemorheologic variables in hypertension.

Authors:  Y Nagakawa; Y Akedo; S Kaku; H Orimo
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

10.  Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound.

Authors:  G Neugebauer; W Akpan; B Kaufmann; K Reiff
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

View more
  18 in total

1.  Partial Agonist and Biased Signaling Properties of the Synthetic Enantiomers J113863/UCB35625 at Chemokine Receptors CCR2 and CCR5.

Authors:  Jenny Corbisier; Alexandre Huszagh; Céline Galés; Marc Parmentier; Jean-Yves Springael
Journal:  J Biol Chem       Date:  2016-11-28       Impact factor: 5.157

Review 2.  Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  C J Dunn; A P Lea; A J Wagstaff
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

3.  Lack of a pharmacokinetic interaction between carvedilol and digitoxin or phenprocoumon.

Authors:  S Harder; R Brei; S Caspary; P G Merz
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

4.  Enantioselective pharmacokinetic and pharmacodynamic properties of carvedilol in spontaneously hypertensive rats: focus on blood pressure variability.

Authors:  Facundo Martín Bertera; Julieta Sofía Del Mauro; Diego Chiappetta; Ariel Héctor Polizio; Fabián Buontempo; Carlos Alberto Taira; Christian Höcht
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-11-03       Impact factor: 3.000

Review 5.  Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D McTavish; D Campoli-Richards; E M Sorkin
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

Review 6.  Antihypertensive profile of carvedilol.

Authors:  W Meyer-Sabellek; B Agrawal
Journal:  Clin Investig       Date:  1992

Review 7.  Pharmacological profile of beta-adrenoceptor blockers with vasodilating properties, especially carvedilol--rationale for clinical use.

Authors:  G Sponer; W Bartsch; K Strein
Journal:  Clin Investig       Date:  1992

8.  Clinical pharmacology of carvedilol.

Authors:  B Tomlinson; B N Prichard; B R Graham; R J Walden
Journal:  Clin Investig       Date:  1992

9.  Metabolomic profiling of cellular responses to carvedilol enantiomers in vascular smooth muscle cells.

Authors:  Mingxuan Wang; Jing Bai; Wei Ning Chen; Chi Bun Ching
Journal:  PLoS One       Date:  2010-11-24       Impact factor: 3.240

10.  Population pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate.

Authors:  Ahmed A Othman; David M Tenero; Duane A Boyle; Natalie D Eddington; Michael J Fossler
Journal:  AAPS J       Date:  2007-06-15       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.